HYUGA PRIMARY CARE Co.,Ltd. (7133) AI Stock Analysis

• Market Cap: ¥9.58B
• Dividend Yield: 1.52%
• Average Volume (3M): 29.57K
• Price to Earnings (P/E): 13.6
• Beta (1Y): 0.34
• Revenue Growth: 18.30%
• EPS Growth: 37.13%
• Country: JP
• Employees: 544
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 8.96
• Shares Outstanding: 7,277,200
• 10 Day Avg. Volume: 14,220
• 30 Day Avg. Volume: 29,566
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥1,434.00
• Price Target Upside: 8.97% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 70 Outperform
• Price Target: ¥1,434.00 ▲(8.97% Upside)

HYUGA PRIMARY CARE Co.,Ltd. has a strong financial foundation with robust revenue growth and profitability. However, technical indicators suggest weak market momentum, which could impact short-term performance. The stock's fair valuation and dividend yield provide some support for investors.

HYUGA PRIMARY CARE Co.,Ltd. Business Overview & Revenue Model

Company Description

HYUGA PRIMARY CARE Co.,Ltd. provides home-visit pharmacies, nursing, and care planning services in Japan. The company offers know-how, systems, human resources, and sales for home visiting pharmacy operations to small and medium-sized pharmacy operators; lends Fam Care, an home visit support information system; On-call system support; and guidance on home palliative care. It also provides Tai Support, a nursing facility search site that offers medical social workers with information on senior housing with services, paid nursing homes, group homes, etc.; Mimamori ICT Robot Terminal, a wearable device for nursing care facilities; operates a home visiting pharmacy that delivers prescription drugs directly to patients; and engages in the primary care home business. The company was formerly known as Hyuga Pharmacy Co., Ltd. and changed its name to HYUGA PRIMARY CARE Co.,Ltd. in October 2020. HYUGA PRIMARY CARE Co.,Ltd. was incorporated in 2007 and is based in Kasuga, Japan.

How the Company Makes Money

HYUGA PRIMARY CARE Co.,Ltd. generates revenue primarily through its healthcare services, which include patient consultations, diagnostic tests, and treatments. The company earns money by charging fees for these medical services, which may be paid directly by the patients or covered by insurance providers. Additionally, the company may have partnerships with local healthcare facilities or insurance companies to expand its reach and enhance service delivery. These collaborations can play a crucial role in driving patient volume and ensuring steady revenue streams.

HYUGA PRIMARY CARE Co.,Ltd. Financial Statement Overview

Summary

HYUGA PRIMARY CARE Co.,Ltd. exhibits strong financial performance with impressive revenue growth, profitability, and cash flow management. The balance sheet shows a disciplined approach to leverage and equity management, although rising liabilities require careful attention.

Income Statement

HYUGA PRIMARY CARE Co.,Ltd. has demonstrated strong revenue growth over recent years, with a notable increase from 4,331 million JPY in 2020 to 9,984 million JPY in 2025. The company has maintained healthy gross profit and net profit margins, indicating efficient cost management and profitability. The EBIT and EBITDA margins further highlight operational efficiency, contributing to a strong financial position.

Balance Sheet

The company's balance sheet reflects a solid equity base, with stockholders' equity increasing significantly over the years. The debt-to-equity ratio has been managed well, showing a stable leverage position. Return on equity has improved, indicating effective use of shareholder funds. However, the total liabilities have also increased, necessitating careful financial management to maintain stability.

Cash Flow

HYUGA PRIMARY CARE Co.,Ltd. has shown consistent growth in free cash flow, supported by strong operating cash flows. The operating cash flow to net income ratio is robust, indicating good cash generation relative to earnings. Despite fluctuations in capital expenditures, the company has managed to maintain positive free cash flow, supporting its operational and expansion activities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.98B	9.98B	8.29B	6.66B	5.78B	5.09B
Gross Profit	2.41B	2.41B	1.88B	1.56B	1.24B	783.83M
EBITDA	1.29B	1.31B	854.38M	627.27M	568.69M	258.55M
Net Income	719.03M	719.03M	441.03M	382.88M	328.45M	97.14M
Balance Sheet
Total Assets	7.05B	7.05B	6.35B	2.91B	2.53B	2.02B
Cash, Cash Equivalents and Short-Term Investments	565.93M	565.93M	688.01M	567.69M	719.56M	538.29M
Total Debt	2.65B	2.65B	2.80B	251.54M	330.21M	447.63M
Total Liabilities	4.68B	4.68B	4.71B	1.43B	1.46B	1.41B
Stockholders Equity	2.37B	2.37B	1.64B	1.48B	1.07B	609.46M
Cash Flow
Free Cash Flow	0.00	485.51M	473.20M	102.59M	228.92M	277.22M
Operating Cash Flow	0.00	771.32M	706.64M	342.25M	484.60M	351.82M
Investing Cash Flow	0.00	-473.98M	-1.13B	-383.39M	-320.25M	-77.59M
Financing Cash Flow	0.00	-419.43M	538.78M	-110.73M	16.93M	36.64M

HYUGA PRIMARY CARE Co.,Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1316.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7133, the sentiment is Neutral. The current price of 1316 is above the 20-day moving average (MA) of 1304.15, below the 50-day MA of 1371.02, and below the 200-day MA of 1339.03, indicating a neutral trend. The MACD of -12.02 indicates Negative momentum. The RSI at 48.70 is Neutral, neither overbought nor oversold. The STOCH value of 85.05 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:7133.

HYUGA PRIMARY CARE Co.,Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2374	78 Outperform	¥20.90B	11.94	8.82%	3.59%	4.31%	-9.01%
2425	77 Outperform	¥3.08B	9.56	12.79%	2.47%	-0.34%	-21.06%
7129	75 Outperform	¥3.28B	11.26	7.90%	2.56%	4.76%	134.83%
7133	70 Outperform	¥9.58B	13.62	―	1.52%	18.30%	37.13%
7091	70 Outperform	¥4.25B	10.36	17.81%	―	15.78%	120.80%
7061	66 Neutral	¥11.28B	20.89	18.56%	1.12%	20.37%	-5.97%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%